The proposed career development award is designed to complement the applicant's basic science background in motivational processes underlying addictive behaviors by supporting a training program in the development and evaluation of motivational interventions for underserved populations with substance use disorders (SUDs). This program will facilitate transition of the applicant to an independent investigator in health services research with specialty in psychosocial interventions for SLID populations with comorbid mental health disorders. The proposed 5 year pilot study examines the incremental efficacy of an aftercare psychosocial treatment program of a motivational intervention combined with cognitive behavioral therapy (CBT), relative to standard care, twelve-step facilitation therapy (TSF) for individuals with stimulant dependence and comorbid major depressive disorder. Although the past decade has seen new cognitive and motivational interventions producing improvement in substance use outcomes, few studies have systematically explored the efficacy of these approaches in combination in patients with substance use disorders and comorbid mental health disorders. The proposed randomized trial will include 80 dually diagnosed individuals with stimulant dependence and a substance-independent diagnosis of Major Depressive Disorder. In patients receiving pharmacotherapy for depression, we will compare 12 weeks of CBT combined with motivational therapy (CBT-MT) to 12 weeks of TSF on 6, 12, 24, and 36 week outcomes for depression, substance use, HIV-risk behaviors, and other healthcare outcomes. The primary hypothesis is that CBT-MT will produce better outcomes than TSF. We will also examine predictors of early attrition and treatment retention and examine neuropsychological predictors of treatment retention and outcome. The results of this study might provide a dual-diagnosis specific, cognitive- motivational alternative to traditional aftercare programs for the treatment of stimulant users with depression.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23DA020085-05
Application #
8127957
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Grossman, Debra
Project Start
2007-09-15
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2011
Total Cost
$167,138
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Glasner-Edwards, Suzette; Mooney, Larissa J; Ang, Alfonso et al. (2017) Mindfulness Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. Mindfulness (N Y) 8:126-135
Glasner-Edwards, Suzette; Mooney, Larissa J (2014) Methamphetamine psychosis: epidemiology and management. CNS Drugs 28:1115-26
Glasner-Edwards, Suzette; Mooney, Larissa J; Ang, Alfonso et al. (2013) Does Posttraumatic Stress Disorder (PTSD) Affect Post-Treatment Methamphetamine Use? J Dual Diagn 9:123-128
Glasner-Edwards, Suzette; Mooney, Larissa J; Marinelli-Casey, Patricia et al. (2011) Bulimia nervosa among methamphetamine dependent adults: association with outcomes three years after treatment. Eat Disord 19:259-69
Glasner-Edwards, Suzette; Mooney, Larissa J; Marinelli-Casey, Patricia et al. (2010) Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug Alcohol Rev 29:12-20
Glasner-Edwards, Suzette; Rawson, Richard (2010) Evidence-based practices in addiction treatment: review and recommendations for public policy. Health Policy 97:93-104
Glasner-Edwards, Suzette; Mooney, Larissa J; Marinelli-Casey, Patricia et al. (2010) Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict 19:385-90
Glasner-Edwards, Suzette; Marinelli-Casey, Patricia; Hillhouse, Maureen et al. (2009) Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis 197:225-31